Ran Nussbaum

Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel.

Pontifax Management Co. Ltd. (Pontifax) is a venture capital firm founded in 2004 by Eliyahu Hurvitz. The firm is headquartered in Herzliya Pituach, Israel.

CollPlant Ltd. specializes in the development and commercialization of medical products. It develops and commercialize tissue repair products for orthobiologics and advanced wound care markets. The company was founded by Tsafrir Feigin Yehuda and Oded Shoseyov in 2004 and is headquartered in Ness Ziona, Israel.

ProtAb Ltd. develops drug treatment for rheumatoid arthritis. It develops therapeutic agents that modulate cytokine regulation, tipping the balance toward anti-inflammatory signaling pathways in the treatment of autoimmune inflammatory diseases. The company was Founded by Yaakov Naparstek in 2005 and is headquartered in Jerusalem, Israel.

Nutrinia Ltd. develops bioactive feed supplements for infant formulas and animal feed. The firm is involved in broad intellectual property protection, industrial processes envelopment, conducting additional clinical trials and obtaining regulatory approval for the supplementation of pre-term and infant formulas with Insulin. The company was founded by Naim Shehadeh in 2003 and is headquartered in Ramat-Gan, Israel.

Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA.

cCAM Biotherapeutics Ltd. is a preclinical-stage company engaging in the development of immunotherapies to treat cancer. The company was founded by Silvia Noiman and Gal Markel in 2010 and is headquartered in Hod Ha'Sharon, Israel.

Quiet Therapeutics Ltd. develops a proprietary nanoparticle-based delivery system for the targeted delivery of chemotherapy and anti-inflammatory drugs. It developed a class of cancer therapeutics called GAGomers, enables the flexibility of delivering a medicine that can kill the cancer cells and block the production of proteins that promote the cancer. The company was founded by Dan Peer and Rimona Margalit in 2009 and is headquartered in Ness Ziona, Israel.

OCON Medical Ltd. engages in the research and development of intrauterine device. Its products include Intrauterine Ball IUB and IUB SCu300. The company was founded by Ilan Baram on 2008 and is headquartered in Modiin, Israel.

Eloxx Pharmaceuticals Ltd. provides biopharmaceutical research and development services. The firm specializes in the discovery, development, and commercialization of drug compounds for the treatment of genetic diseases. It focuses on the treatment of diseases caused by nonsense mutations, including Cystic fibrosis, Duchene Muscular Dystrophy, Usher syndrome, Ataxia-telangiectasia, Beta thalassemia, and Tay-Sachs Hurler syndrome. Its focus areas encompass clinical drug development and target drugs discovery programs. The company was founded by Silvia Noiman and Shmuel Tuvia in 2013 and is headquartered in Herzliya, Israel.

Aliment Capital LLC (Aliment Capital) is a venture capital subsidiary of Pontifax Management Co. Ltd. founded in 2014 by Philip Robert Erlanger and Ben Belldegrun. The firm is headquartered in California, United States.

Fore Biotherapeutics, Inc. develops tumor specific driver mutations. It offers fully automated live-cell screening from NGS data. The company was founded by Haim Gil-Ad and Yoram Altschuler in 2011 and is headquartered in Philadelphia, PA.

N T B Pharma Ltd. provides scientific and technical research development services. The private company is based in Herzliya, Israel.

LB Pharmaceuticals, Inc. provides pharmaceutical services. The company was founded by Vince Grattan and Zachary Prensky in 2015 and is headquartered in New York, NY.

Zolex Therapeutics Ltd. operates as a biotechnology company. It develops orally active, small molecular weight antibioticsthat target straphylococcus aureus. The company is headquartered in Tel Aviv, Israel.

Part of Pontifax Management Co. Ltd., Pontifax (Israel) IV LP is an investment services provider. The company is based in Hertsliya, Israel and was founded in 2015.

Prevail Therapeutics, Inc. develops therapeutics for neurodegenerative diseases. The firm engages in the research and development of novel biologic gene therapies to treat Parkinson's disease and other neurodegenerative diseases. The company was founded by Asa Abeliovich on July 6, 2017 and is headquartered in New York, NY.

Anaveon AG engages in the development of immune therapies against cancer. Its compounds promote effector T-cell functions to enhance a patient?s immune system to respond to tumors. The company was founded on December 11, 2017 by Onur Boyman and Andreas Katopodis and is headquartered in Bottmingen, Switzerland.

Lutris Pharma Ltd. is working on the improvement of the anti-cancer therapy effectiveness and the quality of life for patients that are treated with Epidermal Growth Factor Receptor Inhibitors. The company was founded on December 14, 2015 and is headquartered in Tel Aviv, Israel.

Indapta Therapeutics, Inc. operates as a biotechnology company. It focuses on developing and commercializing a proprietary, first-in-class, off-the-shelf allogeneic cell therapy to treat multiple types of difficult-to-treat hematologic cancers and solid tumors. The company was founded by Guy DiPierro, Ronald A. Martell, Sungjin Kim and John Sunwoo in 2017 and is headquartered in Houston, TX.

Graviton Bioscience Corp. develops novel therapeutics for the treatment of autoimmune, cancer, genetic, fibrotic and other serious diseases. The company is based in New York, NY. The company was founded by Samuel D. Waksal. Samuel D. Waksal has been the CEO since incorporation.